Program
selinexor
Also written as “Selinexor”, “Selinexor (combination therapy)” and “Selinexor 40 mg”.
Its studies are mostly in Multiple Myeloma · Lymphoma, Large B-Cell, Diffuse · Primary Myelofibrosis · Endometrial Neoplasms · Glioblastoma, led by 6 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Karyopharm Therapeutics | 317 open or running | phase 3since Oct 13, 2015 | May 16, 2012 | Dec 2026phase 3 · NCT04442022 |
| Antengene | 40 open or running | phase 2since Apr 30, 2019 | Apr 30, 2019 | none ahead |
| Oncotherapeutics | 22 open or running | phase 1since Aug 12, 2020 | Aug 12, 2020 | Apr 1, 2027phase 1 · NCT06225310 |
| AbbVie | 11 open or running | phase 3since Nov 28, 2023 | Nov 28, 2023 | Dec 2027phase 3 · NCT06158841 |
| Qilu Pharmaceutical | 11 open or running | phase 3since Aug 13, 2025 | Aug 13, 2025 | Dec 2027phase 3 · NCT07138209 |
| Sarah Cannon Research Institute | 11 open or running | phase 2since Mar 1, 2021 | Mar 1, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 26 studies since May 16, 2012.
- Jun 10, 2020Phase 3 study in Lymphoma, Large B-Cell, DiffuseKaryopharm Therapeutics · NCT04442022 · 501 enrolled · United States, China, Israel and more
- Aug 12, 2020Oncotherapeutics's first study: phase 1 study in Multiple MyelomaNew to OncotherapeuticsOncotherapeutics · NCT04519476 · 22 planned · United States
- Sep 9, 2020Phase 2 study in Primary MyelofibrosisKaryopharm Therapeutics · NCT04562870 · 112 enrolled · United States, China, France and more
- Sep 14, 2020Phase 3 study in Primary MyelofibrosisKaryopharm Therapeutics · NCT04562389 · 353 enrolled · United States, Australia, Belgium and more
- Feb 22, 2021Phase 2 study in MelanomaKaryopharm Therapeutics · NCT04768881 · 15 enrolled · United States
- Mar 1, 2021Sarah Cannon Research Institute's first study: phase 2 study in Multiple MyelomaNew to Sarah Cannon Research InstituteSarah Cannon Research Institute · NCT04782687 · 73 enrolled · United States
- Apr 17, 2021Phase 2 study in Colorectal NeoplasmsKaryopharm Therapeutics · NCT04854434 · 13 enrolled · United States
- Feb 9, 2022Phase 2 study in Lymphoma, Large B-Cell, DiffuseAntengene · NCT05265975 · 54 enrolled · China
- Apr 26, 2022Phase 1 study in Lymphoma, Large B-Cell, DiffuseAntengene · NCT05354362 · 7 enrolled · China
- Nov 3, 2022Phase 3 study in Endometrial NeoplasmsKaryopharm Therapeutics · NCT05611931 · 257 enrolled · United States, Australia, Belgium and more
- Jul 24, 2023Phase 2 study in Primary MyelofibrosisKaryopharm Therapeutics · NCT05980806 · 58 planned · United States, Belgium, Bulgaria and more
- Nov 7, 2023Phase 1 study in Multiple MyelomaOncotherapeutics · NCT06225310 · 30 planned · United States
- Nov 28, 2023AbbVie's first study: phase 3 study in Multiple MyelomaNew to AbbVieAbbVie · NCT06158841 · 421 enrolled · United States, Australia, Austria and more
- Aug 13, 2025Qilu Pharmaceutical's first study: phase 3 study in RecurrenceNew to Qilu PharmaceuticalQilu Pharmaceutical · NCT07138209 · 228 planned · China
Ahead
- Dec 2026Primary completion: phase 3 study in Lymphoma, Large B-Cell, DiffuseKaryopharm Therapeutics · NCT04442022
- Dec 2026Primary completion: phase 2 study in Lymphoma, Large B-Cell, DiffuseKaryopharm Therapeutics · NCT02227251
- Apr 1, 2027Primary completion: phase 1 study in Multiple MyelomaOncotherapeutics · NCT06225310
- Jun 2027Primary completion: phase 2 study in Primary MyelofibrosisKaryopharm Therapeutics · NCT05980806
TargetBeta
“An orally available, small molecule inhibitor of CRM1 (chromosome region maintenance 1 protein, exportin 1 or XPO1), ”NCIt, by rule
“Exportin-1 inhibitor”ChEMBL 37, by rule
Other programs on XPO1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| TQB3107 | Sino Biopharmaceutical | phase 1 | 1 |
Studies
All 40 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07138209Recurrence · China | 3 | Recruiting | Qilu Pharmaceutical | Dec 2027 | 228 |
| NCT06158841Multiple Myeloma · United States, Australia, Austria and more | 3 | Active, not recruiting | AbbVie | Dec 2027 | 421 |
| NCT06225310Multiple Myeloma · United States | 1 | Recruiting | Oncotherapeutics | Apr 1, 2027 | 30 |
| NCT05980806Primary Myelofibrosis · United States, Belgium, Bulgaria and more | 2 | Recruiting | Karyopharm Therapeutics | Jun 2027 | 58 |
| NCT05611931Endometrial Neoplasms · United States, Australia, Belgium and more | 3 | Active, not recruiting | Karyopharm Therapeutics | May 22, 2026 | 257 |
| NCT05354362Lymphoma, Large B-Cell, Diffuse · China | 1 | Terminated | Antengene | Feb 6, 2023 | 7 |
| NCT05265975Lymphoma, Large B-Cell, Diffuse · China | 2 | Terminated | Antengene | Dec 31, 2024 | 54 |
| NCT04854434Colorectal Neoplasms · United States | 2 | Terminated | Karyopharm Therapeutics | Jun 24, 2022 | 13 |
| NCT04782687Multiple Myeloma · United States | 2 | Active, not recruiting | Sarah Cannon Research Institute | May 31, 2026 | 73 |
| NCT04768881Melanoma · United States | 2 | Terminated | Karyopharm Therapeutics | Sep 22, 2023 | 15 |
| NCT04562389Primary Myelofibrosis · United States, Australia, Belgium and more | 3 | Active, not recruiting | Karyopharm Therapeutics | Feb 20, 2026 | 353 |
| NCT04562870Primary Myelofibrosis · United States, China, France and more | 2 | Active, not recruiting | Karyopharm Therapeutics | Sep 2026 | 112 |
| NCT04519476Multiple Myeloma · United States | 1 | Recruiting | Oncotherapeutics | Dec 29, 2023 | 22 |
| NCT04442022Lymphoma, Large B-Cell, Diffuse · United States, China, Israel and more | 3 | Active, not recruiting | Karyopharm Therapeutics | Dec 2026 | 501 |
| NCT04414475Multiple Myeloma · Greece, Israel | 2 | Recruiting | Karyopharm Therapeutics | Jan 2028 | 127 |
| NCT04421378Glioblastoma · United States, Canada | 2 | Terminated | Karyopharm Therapeutics | Jul 3, 2023 | 74 |
| NCT04355676Coronavirus Infections | 2 | Withdrawn | Karyopharm Therapeutics | Aug 30, 2020 | 0 |
| NCT04349098Coronavirus Infections · United States, Austria, France and more | 2 | Completed | Karyopharm Therapeutics | Oct 5, 2020 | 190 |
| NCT04256707Carcinoma, Non-Small-Cell Lung · Israel | 2 | Completed | Karyopharm Therapeutics | Jul 31, 2024 | 80 |
| NCT03992339Lymphoma, Large B-Cell, Diffuse · China | 2 | Completed | Antengene | May 31, 2023 | 60 |
| NCT03944057Recurrence · China | 2 | Completed | Antengene | Feb 25, 2022 | 82 |
| NCT03555422Endometrial Neoplasms · United States, Belgium, Canada and more | 3 | Completed | Karyopharm Therapeutics | Jan 22, 2022 | 263 |
| NCT03110562Multiple Myeloma · United States, Australia, Austria and more | 3 | Completed | Karyopharm Therapeutics | Feb 18, 2020 | 402 |
| NCT02628704Multiple Myeloma · United States | 2 | Withdrawn | Karyopharm Therapeutics | Jun 2017 | 0 |
| NCT02606461Liposarcoma · United States, Belgium, Canada and more | 3 | Completed | Karyopharm Therapeutics | Oct 28, 2020 | 342 |
| NCT02431351Myelodysplastic Syndromes | 2 | Withdrawn | Karyopharm Therapeutics | Dec 2017 | 0 |
| NCT02389543Multiple Myeloma | 2 | Withdrawn | Karyopharm Therapeutics | Jan 2018 | 0 |
| NCT02367690Diabetic Foot · New Zealand | 2 | Withdrawn | Karyopharm Therapeutics | May 2015 | 0 |
| NCT02336815Multiple Myeloma · United States, Austria, Belgium and more | 2 | Completed | Karyopharm Therapeutics | Jul 26, 2019 | 202 |
| NCT02314247Lymphoma, T-Cell, Peripheral · Australia, Singapore | 2 | Terminated | Karyopharm Therapeutics | Jan 2016 | 16 |
| NCT02227251Lymphoma, Large B-Cell, Diffuse · United States, Australia, Austria and more | 2 | Active, not recruiting | Karyopharm Therapeutics | Dec 2026 | 244 |
| NCT02213133Carcinoma, Squamous Cell · United States, Canada | 2 | Terminated | Karyopharm Therapeutics | Dec 10, 2015 | 45 |
| NCT02146833Prostatic Neoplasms · United States | 2 | Terminated | Karyopharm Therapeutics | Apr 1, 2016 | 20 |
| NCT02138786Richter's Transformation · United States, Germany, Poland and more | 2 | Terminated | Karyopharm Therapeutics | Aug 31, 2016 | 27 |
| NCT02088541Leukemia, Myeloid, Acute · United States, Canada, Denmark and more | 2 | Completed | Karyopharm Therapeutics | Jan 8, 2018 | 317 |
| NCT02025985Ovarian Neoplasms · Belgium, Denmark | 2 | Completed | Karyopharm Therapeutics | Jan 24, 2017 | 116 |
| NCT01986348Glioblastoma · United States, Denmark, Netherlands | 2 | Terminated | Karyopharm Therapeutics | Jan 23, 2020 | 76 |
| NCT01896505Sarcoma · United States, Canada | 1 | Completed | Karyopharm Therapeutics | Oct 21, 2016 | 54 |
| NCT01607905Carcinoma, Squamous Cell · United States, Canada, Denmark | 1 | Completed | Karyopharm Therapeutics | Mar 15, 2016 | 192 |
| NCT01607892Hematologic Neoplasms · United States, Canada, Denmark | 1 | Completed | Karyopharm Therapeutics | Oct 13, 2015 | 286 |
How it is read
Names in the registry
- “Selinexor”, 32 entries
- “Selinexor (combination therapy)”, 3 entries
- “Selinexor 40 mg”, 2 entries
- “Selinexor 60 mg”, 2 entries
- “ATG-010”, 2 entries
Conditions, from the studies’ own filings
- Multiple Myeloma, 11 studies
- Lymphoma, Large B-Cell, Diffuse, 5 studies
- Primary Myelofibrosis, 3 studies
- Endometrial Neoplasms, 2 studies
- Glioblastoma, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.